Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al
- PMID: 27934677
- DOI: 10.1136/annrheumdis-2016-210631
Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al
Keywords: Anti-TNF; Outcomes research; Rheumatoid Arthritis.
Comment on
-
Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8. Ann Rheum Dis. 2017. PMID: 27502891 Free PMC article.
-
Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?Ann Rheum Dis. 2017 Feb;76(2):e3. doi: 10.1136/annrheumdis-2016-210566. Epub 2016 Oct 14. Ann Rheum Dis. 2017. PMID: 27742658 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
